-
公开(公告)号:US11920196B2
公开(公告)日:2024-03-05
申请号:US17337163
申请日:2021-06-02
Applicant: University Health Network
Inventor: Mohit Kapoor , Rajiv Gandhi , Shabana Amanda Ali
IPC: C12Q1/6876
CPC classification number: C12Q1/6876 , C12Q2600/178
Abstract: A method comprising obtaining a substantially cell-free sample of blood plasma or blood serum from a subject with osteoarthritis; and detecting a presence of or measuring a level of novel_miRNA_1 (gucuggcucaggguuggg) (SEQ ID NO: 1), novel_miRNA_2 (ucccuguucgggcgccacu) (SEQ ID NO: 2), novel_miRNA_3 (uguuuagcauccuguagccugc) (SEQ ID NO: 3), and novel_miRNA_4 (uaguggguuaucagaacu) (SEQ ID NO: 4). Also provided are methods where additional miRNAs are detected including novel miRNA 5 (SEQ ID NO: 5), novel miRNA 6 (SEQ ID NO: 6), novel miRNA 7 (SEQ ID NO: 7), novel miRNA 8 (SEQ ID NO: 8), novel miRNA 9 (SEQ ID NO: 9), novel miRNA 10 (SEQ ID NO: 10), novel miRNA 11 (SEQ ID NO: 11), novel miRNA 12 (SEQ ID NO: 12), novel miRNA 13 (SEQ ID NO: 13), hsa-miR-335-3p, hsa-miR-199a-5p, hsa-miR-671-3p, hsa-miR-1260b, hsa-miR-191-3p, hsa-miR-335-5p and/or hsa-miR-543.
-
公开(公告)号:US11908568B2
公开(公告)日:2024-02-20
申请号:US17077413
申请日:2020-10-22
Inventor: Ting Xia , Zhou Yu , Patrik Rogalla , Bernice Hoppel
CPC classification number: G16H30/20 , G06N3/04 , G06T7/0014 , G16H50/20 , G16H50/30 , G06T2207/10028 , G06T2207/10081 , G06T2207/30168
Abstract: The present disclosure relates to a method for patient-specific optimization of imaging protocols. According to an embodiment, the present disclosure relates to a method for generating a patient-specific imaging protocol, comprising acquiring scout scan data, the scout scan data including scout scan information and scout scan parameters, generating a simulated image based on the acquired scout scan data, deriving a simulated dose map from the generated simulated image, determining image quality of the generated simulated image by applying machine learning to the generated simulated image, the neural network being trained to generate at least one probabilistic quality representation corresponding to at least one region of the generated simulated image, evaluating the determined image quality relative to a image quality threshold and the derived simulated dose map relative to a dosage threshold, optimizing. based on the evaluating, scan acquisition parameters and image reconstruction parameters, and generating, optimal imaging protocol parameters, wherein the optimal imaging protocol parameters maximize image quality while minimizing radiation exposure.
-
23.
公开(公告)号:US20230330152A1
公开(公告)日:2023-10-19
申请号:US18336410
申请日:2023-06-16
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: Gordon KELLER , April M. CRAFT
CPC classification number: A61K35/32 , C12N5/0655 , G01N33/5044 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/415 , C12N2501/999 , C12N2503/02 , C12N2506/02 , C12N2506/03
Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising:
a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising:
i. a FGF agonist;
ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and
iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939;
to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta;
b. generating a chondrocyte precursor population comprising:
i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media;
ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and
c. either
i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or
ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.-
24.
公开(公告)号:US20230302096A1
公开(公告)日:2023-09-28
申请号:US18047129
申请日:2022-10-17
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: Philippe P. MONNIER , Nardos G. TASSEW
IPC: A61K38/44 , A61K31/137 , C07K16/28 , A61K31/724 , A61K31/365 , A61K31/7048 , A61K38/48 , C07K14/435 , C07K14/705 , G01N33/53 , A61K31/495 , A61K38/17 , G01N33/50
CPC classification number: A61K38/443 , A61K31/137 , C07K16/28 , C12Y101/03006 , A61K31/724 , A61K31/365 , A61K31/7048 , A61K38/482 , C07K14/435 , C07K14/705 , G01N33/53 , A61K31/495 , A61K38/177 , G01N33/5058 , A61K2039/505
Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.
-
公开(公告)号:US11766437B2
公开(公告)日:2023-09-26
申请号:US16635320
申请日:2018-08-01
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: Mark Robert Bray , Jacqueline M. Mason , Tak W. Mak , Graham Fletcher
IPC: A61K31/519 , A61P35/00 , A61K39/395
CPC classification number: A61K31/519 , A61K39/3955 , A61P35/00
Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
-
26.
公开(公告)号:US11751817B2
公开(公告)日:2023-09-12
申请号:US15701091
申请日:2017-09-11
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: T. Douglas Bradley , Geoffrey Roy Fernie , Hisham Alshaer , Ahmad Ziad Akl
CPC classification number: A61B5/7282 , A61B5/7475 , A61B7/003 , A61B5/4818 , A61B5/6803
Abstract: Disclosed herein are breathing disorder identification, characterization and diagnosis methods, devices and systems. In general the disclosed methods, devices and systems may rely on the characterization of breath sound amplitudes, periodic breath sounds and/or aperiodic breath sounds to characterize a breathing disorder as obstructive (e.g. obstructive sleep apnea—OSA) or non-obstructive (e.g. central sleep apnea—CSA).
-
27.
公开(公告)号:US20230263400A1
公开(公告)日:2023-08-24
申请号:US17456001
申请日:2020-05-27
Inventor: Daniyal LIAQAT , Mohamed ABDALLA , Eyal DE LARA , Frank RUDZICZ , Andrea GERSHON , Robert Wu
CPC classification number: A61B5/02 , A61B5/7275
Abstract: Systems and methods for filtering time-varying data for filtering and extracting a predicted physiological signal. A method including: segmenting the time-varying data into temporal windows; using a trained filter machine learning model, predicting an error for each prediction of the physiological signal for each window of time-varying data, the filter machine learning model trained using physiological signal predictions based on training time-varying data and known values of the physiological signal for the training time-varying data; discarding each window of time-varying data when the predicted error for such window is greater than a threshold; and where the window of time-varying data is not discarded, outputting at least one of the window of time-varying data and the predicted error for each prediction of the physiological signal.
-
公开(公告)号:US20230257769A1
公开(公告)日:2023-08-17
申请号:US18098328
申请日:2023-01-18
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: Valerie WALLACE , Arturo ORTIN-MARTINEZ
CPC classification number: C12N15/8509 , A61K35/30 , A61P27/02
Abstract: There is described herein a photoreceptor cell comprising a neurotoxin transgene, methods for making the same, and use of the same for vision treatment.
-
29.
公开(公告)号:US20230245315A1
公开(公告)日:2023-08-03
申请号:US18148861
申请日:2022-12-30
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: Ralph DACOSTA
CPC classification number: G06T7/0016 , A61B5/0071 , A61B5/0077 , A61B5/445 , G01N21/6486 , G06T2207/10016 , G06T2207/10024 , G06T2207/10048 , G06T2207/10064 , G06T2207/30088 , G06T2207/30096
Abstract: An adaptor for configuring a mobile communication device for tissue imaging is disclosed. The adaptor includes a housing configured to be removably coupled to a mobile communication device, at least one excitation light source for fluorescent imaging, a white light source for white light imaging, and a power source for powering the adaptor. The excitation light source is configured to emit light in one of ultraviolet, visible, near-infrared, and infrared ranges.
-
公开(公告)号:US20230203473A1
公开(公告)日:2023-06-29
申请号:US18061273
申请日:2022-12-02
Applicant: University Health Network , Sinai Health System
Inventor: Daniel DINIZ DE CARVALHO , Shu Yi SHEN , Rajat SINGHANIA , Scott Victor BRATMAN , Ankur RAVINARAYANA CHAKRAVARTHY
IPC: C12N15/10 , C12Q1/6806 , C12Q1/6804 , G01N33/53
CPC classification number: C12N15/1003 , C12N15/1093 , C12N15/10 , C12Q1/6806 , C12Q1/6804 , G01N33/5308 , C12Q1/6886
Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.
-
-
-
-
-
-
-
-
-